Coya Therapeutics, Inc.
COYANASDAQHealthcare● Active
$4.61
+$0.06(+1.21%)
Market Cap$83851303
P/E Ratio—
52W High$7.75
52W Low$3.71
Coya Therapeutics, Inc. (COYA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
COYA · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
-$0.32
Est. -$0.39 · +17.9%
Revenue
$0.00B
Est. $0.00B · +100.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
COYA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.36 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 12, 2026 | -$0.39 | -$0.32 | +17.9% | $0.00B | $0.00B | +100.0% |
| ▼ Q1 FY2026 | Mar 16, 2026 | -$0.27 | -$0.34 | -24.8% | $0.00B | $0.00B | +78.0% |
| ▼ Q4 FY2025 | Nov 12, 2025 | $0.02 | -$0.10 | -600.0% | $0.00B | $0.00B | +85.1% |
| ▼ Q3 FY2025 | Aug 12, 2025 | -$0.22 | -$0.36 | -63.6% | $0.00B | $0.00B | -79.1% |
| — Q2 FY2025 | May 13, 2025 | -$0.44 | -$0.44 | +0.0% | $0.00B | $0.00B | -90.2% |
| ▲ Q1 FY2025 | Mar 18, 2025 | -$0.26 | -$0.18 | +30.8% | $0.00B | $0.00B | -98.0% |
| ▲ Q4 FY2024 | Nov 6, 2024 | -$0.41 | -$0.26 | +36.6% | — | $0.00B | — |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.36
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 12, 2026Beat
EPS Actual
-$0.32
EPS Est.
-$0.39
EPS Surpr.
+17.9%
Revenue
$0.00B
Q1 FY2026
Mar 16, 2026Miss
EPS Actual
-$0.34
EPS Est.
-$0.27
EPS Surpr.
-24.8%
Revenue
$0.00B
Q4 FY2025
Nov 12, 2025Miss
EPS Actual
-$0.10
EPS Est.
$0.02
EPS Surpr.
-600.0%
Revenue
$0.00B
Q3 FY2025
Aug 12, 2025Miss
EPS Actual
-$0.36
EPS Est.
-$0.22
EPS Surpr.
-63.6%
Revenue
$0.00B
Q2 FY2025
May 13, 2025
EPS Actual
-$0.44
EPS Est.
-$0.44
EPS Surpr.
+0.0%
Revenue
$0.00B
Q1 FY2025
Mar 18, 2025Beat
EPS Actual
-$0.18
EPS Est.
-$0.26
EPS Surpr.
+30.8%
Revenue
$0.00B
Q4 FY2024
Nov 6, 2024Beat
EPS Actual
-$0.26
EPS Est.
-$0.41
EPS Surpr.
+36.6%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.35 | $-0.35 | $-0.35 | 1 |
| Q3 FY2028 | $0.74 | $0.74 | $0.74 | 1 |
| Q2 FY2028 | $-0.29 | $-0.29 | $-0.29 | 1 |
| Q1 FY2028 | $-0.31 | $-0.31 | $-0.31 | 1 |
| Q4 FY2027 | $-0.35 | $-0.35 | $-0.35 | 1 |
| Q3 FY2027 | $-0.24 | $-0.24 | $-0.24 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 4 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 4 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 5 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 2 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 12, 2026 | +17.9% | $4.18 | $4.29 | +2.63% |
| ▼ Q1 FY2026 | Mar 16, 2026 | -24.8% | $4.53 | $4.50 | -0.66% |
| ▼ Q4 FY2025 | Nov 12, 2025 | -600.0% | $6.01 | $6.09 | +1.33% |
| ▼ Q3 FY2025 | Aug 12, 2025 | -63.6% | $6.15 | $6.13 | -0.33% |
| ▲ Q2 FY2025 | May 13, 2025 | +0.0% | $6.14 | $5.76 | -6.19% |
| ▲ Q1 FY2025 | Mar 18, 2025 | +30.8% | $6.85 | $6.45 | -5.84% |
| ▲ Q4 FY2024 | Nov 6, 2024 | +36.6% | $6.74 | $7.26 | +7.72% |
| ▼ Q3 FY2024 | Aug 12, 2024 | -35.7% | $6.06 | $5.28 | -12.87% |
Q2 FY2026+2.63%
Report Date
May 12, 2026
EPS Beat/Miss
+17.9%
Price Before
$4.18
Price After
$4.29
Q1 FY2026-0.66%
Report Date
Mar 16, 2026
EPS Beat/Miss
-24.8%
Price Before
$4.53
Price After
$4.50
Q4 FY2025+1.33%
Report Date
Nov 12, 2025
EPS Beat/Miss
-600.0%
Price Before
$6.01
Price After
$6.09
Q3 FY2025-0.33%
Report Date
Aug 12, 2025
EPS Beat/Miss
-63.6%
Price Before
$6.15
Price After
$6.13
Q2 FY2025-6.19%
Report Date
May 13, 2025
EPS Beat/Miss
+0.0%
Price Before
$6.14
Price After
$5.76
Q1 FY2025-5.84%
Report Date
Mar 18, 2025
EPS Beat/Miss
+30.8%
Price Before
$6.85
Price After
$6.45
Q4 FY2024+7.72%
Report Date
Nov 6, 2024
EPS Beat/Miss
+36.6%
Price Before
$6.74
Price After
$7.26
Q3 FY2024-12.87%
Report Date
Aug 12, 2024
EPS Beat/Miss
-35.7%
Price Before
$6.06
Price After
$5.28
Avg Beat Reaction-0.42%
Avg Miss Reaction-3.13%
Beat Rate4 / 8 quarters
Largest Move-12.87% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: COYA ends December
Coya Therapeutics, Inc. (COYA) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $-0.32 — beating the analyst consensus of $-0.39 by +17.9%. The next COYA earnings date is expected around September 1, 2026.
Each quarter, investors track COYA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. COYA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
COYA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
COYA earnings · 5 questionsCoya Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. COYA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; COYA historically reports after market close (AMC).
COYA earnings datewhen is COYA earningsCOYA next earnings datewhen does COYA report earningsCOYA earnings calendar
▸ Source: FMP · Coya Therapeutics, Inc. SEC filings · US GAAP · Coya Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026